Mark Rekhter

Mark Rekhter has extensive work experience in the pharmaceutical industry. Mark started their career at Pfizer as a Research Associate from January 2000 to December 2002. In January 2003, they joined Eli Lilly and Company as a Senior Research Scientist until January 2004. Mark then served as a Research Advisor from January 2004 to January 2009 and later as a Senior Research Advisor from January 2002 to April 2019. Most recently, Mark Rekhter worked at Valo Health as an Executive Director from April 2019 to September 2020, and then as the Head of Cardiometabolic Discovery from September 2020 to the present.

Mark Rekhter received their medical education from Ivanovo State Medical Institute (Ivanovo, Russia) between 1978 and 1984, where they obtained an M.D. degree with a field of study in Medicine. Mark later pursued further studies at the 2nd Moscow Medical Institute between 1985 and 1987, earning a Ph.D. with a focus in Experimental pathology, histology, and embryology.